Speech pathologists and psychologists across Australia & New Zealand will now be able to conduct a valid remote clinical assessment via a telehealth consult from the Coviu platform.
Pearson Clinical's digital stimulus books from two assessment have been integrated into Coviu's technology, meaning both the provider and patient receive perfect visual quality. The focus is on the WISC-5A&NZ and the CELF-5A&NZ.
Telehealth-delivered assessments have been scientifically validated to achieve comparable results to in-person assessments.
To that end, Coviu has worked with Pearson Clinical to develop the best patient and clinician experience. A core part of that experience is an asymmetrical user interface. This allows for the child that is being assessed to only see the assessor and the stimulus book without being distracted by any other user interface elements during the course of the assessment.
In contrast, the assessor will be able to see the child, even enlarge their video, and track the child's clicks on the images. Numbered markers appear on the assessor's end, which enables them to review the child's interactions. Recording of the assessment results will continue to be done in paper-based forms.
The partnership has come at an important time, given the COVID-19 pandemic that has switched many speech pathologists and psychologists to telepractice. Not only can practitioners now perform clinical assessments remotely, but they can continue to provide long-term telehealth services to rural and remote dwellers, disabled or mobility impaired individuals or time-poor urban families.
The relationship between Coviu and Pearson Clinical has been built over several years of collaboration. Scientists have engaged in multiple research projects with both companies to determine the best approach in achieving valid results from telehealth delivered tests. The results were published and continue to be overwhelmingly positive, suggesting that video consultations are a great way to provide care and achieve optimal health outcomes.
Earlier this year, Coviu secured funding from the Jobs for NSW program to support the creation of a partnership between Coviu and US-based Pearson Clinical corporate to take the scientific results forward for a commercial partnership. Subsequently, a CELF-5A&NZ trial was started to gain insights into clinician behaviour and outcomes.
This new partnership has emerged during the COVID-19 crisis and has sped up joint commercialisation. The partnership was only possible because of the previous work undertaken for the clinical validation. It is another step forward in removing barriers to healthcare access, and will enable practitioners to treat a greater demographic of patients.
The assessments are available now to all Coviu users in our add-on marketplace at a price of $20/month/account for unlimited assessments in your account.